KOSDAQBiotech & Pharma142280

GC Medical Science

₩3,340▼ 0.60%2026-10-02 close

Market Cap

₩79.7B

Turnover

₩800M

Volume

240,000 shares

Shares out.

24M

PER

—

PBR

1.3×

EPS

-₩95

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Operating Profit Improves, but Quarterly Earnings Swing Widens

GC Biopharma MS has expanded operating profit for three consecutive years from 2023 to 2025 after exiting a loss, but in the second quarter of 2026 it posted a net loss attributable to owners even as operating profit stayed positive, leaving the quality of earnings to be verified going forward.

1
2025 revenue reached KRW 108.4 billion with operating profit of KRW 2.89 billion (2.7% margin), marking a third straight year of operating profit growth since the 2022 loss.
2
Quarterly revenue slowed for four consecutive quarters from KRW 30.4 billion in Q2 2025 to KRW 23.6 billion in Q1 2026, before rebounding to KRW 27.1 billion in Q2 2026.
3
In Q2 2026, operating profit remained positive at KRW 742 million, but the company posted a net loss attributable to owners of KRW 4.03 billion, diverging from the operating-level trend.
4
As a result, the sum of net income attributable to owners over the most recent four quarters (Q3 2025 through Q2 2026) turned negative at roughly KRW -2.16 billion.
5
The debt ratio declined for four straight years from 170.6% in 2022 to 95.2% in 2025, and operating cash flow remained positive throughout all four years.

Business structure

GC Biopharma MS was established in 2003 with the business purpose of manufacturing and selling in-vitro diagnostic reagents and medical devices, and is an affiliate of the GC Group (formerly Green Cross Group), with GC Biopharma (Green Cross Corp.) as its largest shareholder.

The company's business is centered on diagnostic reagents, dialysis solution, and blood glucose/diabetes-related products; as of 2025, the revenue mix was approximately 52% diagnostic reagents, 29% dialysis solution, 15% blood glucose, 2% home healthcare, and 2% other, with diagnostic reagents and dialysis solution together accounting for more than 80% of revenue.

The blood bag business, formerly one of four core segments, was spun off and divested in May 2020, reshaping the company into its current structure.

The company maintains a wide domestic sales network supplying public health centers, screening centers, internal medicine, dermatology and plastic surgery clinics, hospitals, general hospitals, and university hospitals.

Overseas, it exports diagnostic reagents and medical devices to the United States, Russia, Africa, Latin America, the Middle East, and across Asia, pursuing expansion as an export-oriented global medical device company. Management changed in March 2025, with CEO Sakong Yeong-hee replaced by CEO Kim Yeon-geun.

Under the standard industry classification for medical supplies and other pharmaceutical-related product manufacturing, the company ranks around eighth in the industry by revenue.

Through its corporate materials, the company has outlined diversification plans including expanding dialysis solution production capacity, upgrading real-time molecular diagnostic reagents, developing integrated point-of-care systems for blood glucose, HbA1c, and lipid measurement, and expanding into companion animal point-of-care diagnostics.

Earnings trend

Quarterly revenue · Operating profit

₩30.4B₩1.1B25Q2₩26.4B₩900M25Q3₩25B₩400M25Q4₩23.6B₩300M26Q1₩27.1B₩700M26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩113.1B-₩1.3B2022₩94B₩1.8B2023₩103.9B₩2.3B2024₩108.4B₩2.9B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩30.4B	₩1.1B	3.5%
2025Q3	₩26.4B	₩900M	3.6%
2025Q4	₩25B	₩400M	1.6%
2026Q1	₩23.6B	₩300M	1.2%
2026Q2	₩27.1B	₩700M	2.7%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩113.1B	-₩1.3B	-₩3.6B	−1.1%	−10.8%	170.6%
2023	₩94B	₩1.8B	₩1.8B	1.9%	5.2%	145.2%
2024	₩103.9B	₩2.3B	₩3.6B	2.2%	8.7%	102.6%
2025	₩108.4B	₩2.9B	₩3.7B	2.7%	8.3%	95.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23

Earnings analysis

GC Biopharma MS's annual results improved for three consecutive years after a 2022 loss, when revenue was KRW 113.11 billion, operating loss was KRW 1.26 billion, and net loss attributable to owners was KRW 3.58 billion.

In 2023, the company turned profitable with revenue of KRW 94.01 billion, operating profit of KRW 1.80 billion (1.9% margin), and net income attributable to owners of KRW 1.80 billion, and continued improving in 2024 with revenue of KRW 103.85 billion, operating profit of KRW 2.33 billion (2.2% margin), and net income attributable to owners of KRW 3.58 billion.

In 2025, revenue reached KRW 108.41 billion, operating profit KRW 2.89 billion, operating margin 2.7%, and net income attributable to owners KRW 3.67 billion, the highest levels across the four-year window for both revenue and profit.

On a quarterly basis, revenue and profit peaked in Q2 2025 (revenue KRW 30.44 billion, operating profit KRW 1.06 billion, net income attributable to owners KRW 2.60 billion) before slowing for three consecutive quarters through Q3 2025 (KRW 26.45bn/KRW 0.94bn/KRW 1.36bn), Q4 2025 (KRW 25.05bn/KRW 0.39bn/KRW 0.37bn), and Q1 2026 (KRW 23.55bn/KRW 0.29bn/KRW 0.14bn).

In Q2 2026, revenue rebounded to KRW 27.11 billion and operating profit improved to KRW 0.74 billion, yet the company reported a net loss attributable to owners of KRW 4.03 billion, diverging from the operating-level trend.

As a result, the four-quarter sum of net income attributable to owners from Q3 2025 through Q2 2026 turned negative at roughly KRW -2.16 billion. Operating cash flow remained positive across all four years, at KRW 10.88 billion in 2022, KRW 4.24 billion in 2023, KRW 3.66 billion in 2024, and KRW 7.20 billion in 2025.

The debt ratio fell for four consecutive years, from 170.6% in 2022 to 145.2% in 2023, 102.6% in 2024, and 95.2% in 2025, reflecting an improving financial structure.

Industry analysis

The markets in which the company operates—in-vitro diagnostics (IVD), dialysis solution, and blood glucose meters—are expected to see modest demand growth driven by domestic population aging and rising chronic disease burden from diabetes and chronic kidney disease.

Dialysis solution demand is directly linked to the number of chronic kidney failure patients requiring dialysis and is viewed as having a relatively stable long-term demand base as the elderly population grows.

The blood glucose meter market is a competitive arena where large global players and domestic firms compete simultaneously on price and technology.

The diagnostic reagent segment is subject to demand volatility tied to infectious disease events, and the stock has previously been categorized as a related theme play during past COVID-19 and mpox outbreaks.

The company ranks around eighth in the industry by revenue under the standard industry classification for medical supplies and other pharmaceutical-related product manufacturing, and its affiliation with the GC Group provides a distribution and sales channel advantage.

However, its parent GC Biopharma is undergoing group-wide portfolio restructuring, including the recent divestiture of its stake in GC Biopharma Wellbeing, placing the group in a transitional phase of intra-affiliate business realignment.

Outlook

The company has not presented separate quantitative guidance in recent earnings disclosures, but its corporate materials outline diversification plans including expanding dialysis solution production capacity, upgrading real-time molecular diagnostic reagents based on proprietary recombinant antibody generation technology, developing integrated point-of-care systems for blood glucose, HbA1c, and lipid measurement, and expanding into companion animal point-of-care diagnostics.

On the export front, the company continues to pursue expansion of diagnostic reagent and medical device exports to the United States, Russia, Africa, Latin America, and the Middle East.

At the group level, parent GC Biopharma is undergoing restructuring to concentrate resources on plasma-derived therapies and vaccines, and portfolio adjustments such as the divestiture of GC Biopharma Wellbeing could indirectly affect the business direction of affiliate GC Biopharma MS.

Q1 2026 results showed a swing to net profit even as revenue declined year over year, suggesting internal cost-efficiency efforts are underway in parallel.

In contrast, the specific cause of the Q2 2026 net loss has not been disclosed in detail so far, and whether it was a one-off item will need to be confirmed through future regular filings or third-quarter results.

Valuation

PER

—

PBR

1.3×

ROE

-4.4%

EPS

-₩95

BPS

₩2,428

Dividend per share

₩0

The price-to-book ratio sits in a range that is somewhat above net asset value. With the four-quarter sum of net income attributable to owners having turned negative, earnings-based multiples have entered a range that is difficult to interpret.

The company has maintained a no-dividend policy over the past four years, limiting its appeal from a dividend perspective.

The three consecutive years of operating profit improvement from 2023 through 2025 is a fundamental data point worth noting, but the slowdown in quarterly revenue in 2026 and the Q2 net loss attributable to owners send a conflicting signal.

Market expectations may shift depending on whether both a revenue rebound and a return to net profit are confirmed in third-quarter results.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23

Bull factors

Three straight years of operating profit improvement

Operating profit rose for three consecutive years from KRW 1.80 billion in 2023 to KRW 2.33 billion in 2024 and KRW 2.89 billion in 2025, with the operating margin also climbing from 1.9% to 2.2% to 2.7%.

The shift away from the 2022 operating loss of KRW 1.26 billion into a stable profit structure is a positive fundamental signal. Revenue also grew from KRW 94.01 billion in 2023 to KRW 108.41 billion in 2025, meaning the profit improvement was accompanied by revenue growth.

Stable cash generation

Operating cash flow remained positive at KRW 10.88 billion even during the 2022 loss year, and stayed positive every year from 2023 through 2025. In 2025, operating cash flow reached KRW 7.20 billion, showing that cash generation improved alongside earnings.

The fact that a cash-based financial cushion has been maintained even during periods of earnings volatility is worth noting for financial stability.

GC Group distribution network and export diversification

The company maintains a broad domestic sales network spanning public health centers, screening centers, clinics, general hospitals, and university hospitals, and as a GC Group affiliate can share distribution and sales infrastructure.

Overseas, it has diversified its export network across the United States, Russia, Africa, Latin America, and the Middle East, reducing dependence on any single region. This diversification of domestic and overseas channels can serve as a buffer if demand slows in any single segment.

Bear factors

Quarterly revenue slowdown

Revenue peaked at KRW 30.44 billion in Q2 2025 before declining for three straight quarters to KRW 26.45 billion in Q3 2025, KRW 25.05 billion in Q4 2025, and KRW 23.55 billion in Q1 2026. Q1 2026 revenue was reported as down 11.1% year over year.

Although revenue rebounded to KRW 27.11 billion in Q2 2026, the overall first-half trend appears to have remained lower year over year, and continued stagnation could weigh on the sustainability of the operating profit improvement.

Q2 shift to net loss

In Q2 2026, operating profit stayed positive at KRW 742 million, yet the company posted a net loss attributable to owners of KRW 4.03 billion, diverging from the operating-level trend.

As a result, the four-quarter sum of net income attributable to owners from Q3 2025 through Q2 2026 also turned negative at roughly KRW -2.16 billion. The specific background of the loss has not been disclosed in detail so far, leaving uncertainty until it is confirmed whether the item was one-off.

Debt burden remains elevated

The debt ratio fell for four consecutive years from 170.6% in 2022 to 95.2% in 2025, but it remains close to 100%. Given that absolute profit levels are still modest relative to revenue scale, financial buffer capacity against external shocks may be limited.

Whether the debt ratio improvement trend continues will likely be a key variable in assessing the company's financial structure going forward.

Risk factors

Earnings volatility and disclosure uncertainty

If cases like Q2 2026, where operating profit and net income diverge in direction, recur, this could affect investor confidence in forecasting results. The detailed cause of the net loss has not been disclosed so far and will need to be confirmed through future regular filings.

Given the relatively high quarterly revenue volatility, it is difficult to draw firm conclusions about the annual trend from any single quarter's results.

Intensifying competition

Price and technology competition with domestic and global rivals continues in the diagnostic reagent and blood glucose meter markets. Demand volatility tied to infectious disease events also remains a factor that can affect diagnostic reagent sales. Intensifying competition could pressure not only revenue growth but also margin defense.

Group portfolio restructuring risk

Parent GC Biopharma has recently been restructuring its group portfolio, including the divestiture of its stake in GC Biopharma Wellbeing, and this intra-affiliate business realignment could also affect GC Biopharma MS. Management also changed in March 2025 with a new CEO taking over. Group-level strategic direction could shift the subsidiary's business priorities or resource allocation.

What to watch next

Late October to early November 2026
Q3 2026 preliminary earnings are expected to be disclosed - it will be important to check whether the Q2 net loss was one-off and whether the revenue rebound continues.
Mid-November 2026
The Q3 quarterly report (regular filing) should be reviewed to identify the specific cause of the Q2 net loss, such as non-operating income/expense items.
March 2027
The 2026 annual business report (confirmed full-year results) should be checked to reassess whether the annual operating profit improvement trend continued and to confirm dividend policy.
Around late October 2026, when GC Biopharma group announces Q3 results
Parent GC Biopharma's Q3 group earnings announcement should be checked for the direction of portfolio restructuring and any mention of affiliate-related developments.

Overall view

GC Biopharma MS has shown a gradual fundamental recovery since exiting its 2022 loss, with operating profit and operating margin improving for three consecutive years from 2023 to 2025 and the debt ratio steadily declining.

Operating cash flow staying positive across all four years, including the loss year, is also a positive factor for financial stability.

However, quarterly revenue slowed for four consecutive quarters after Q2 2025 before rebounding in Q2 2026, and in that same quarter, despite positive operating profit, the company posted a net loss attributable to owners of KRW 4.03 billion, turning the four-quarter sum of net income negative—suggesting the quality of earnings warrants closer scrutiny.

Since the detailed background of the net loss has not yet been disclosed, confirmation through Q3 results and regular filings will be an important next step.

The broad distribution network and export diversification tied to the GC Group remain strengths, but the ongoing portfolio restructuring at the parent level is a transitional factor that should also be weighed.

Overall, the company is in a phase where multi-year revenue and profit improvement coexists with recent quarterly earnings volatility, and subsequent disclosures will be key to forming a clearer picture.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.